25 XP   0   0   10

Gland Pharma Limited
Buy, Hold or Sell?

Let's analyse Gland Pharma Limited together

PenkeI guess you are interested in Gland Pharma Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Gland Pharma Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Gland Pharma Limited

I send you an email if I find something interesting about Gland Pharma Limited.

Quick analysis of Gland Pharma Limited (30 sec.)










What can you expect buying and holding a share of Gland Pharma Limited? (30 sec.)

How much money do you get?

How much money do you get?
INR0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
INR483.19
Expected worth in 1 year
INR677.74
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
INR194.55
Return On Investment
11.3%

For what price can you sell your share?

Current Price per Share
INR1,728.35
Expected price per share
INR1,671 - INR1,879
How sure are you?
50%

1. Valuation of Gland Pharma Limited (5 min.)




Live pricePrice per Share (EOD)

INR1,728.35

Intrinsic Value Per Share

INR-156.32 - INR151.96

Total Value Per Share

INR326.87 - INR635.16

2. Growth of Gland Pharma Limited (5 min.)




Is Gland Pharma Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$955m$858.9m$96.1m10.1%

How much money is Gland Pharma Limited making?

Current yearPrevious yearGrowGrow %
Making money$93.7m$145.3m-$51.6m-55.1%
Net Profit Margin21.5%27.6%--

How much money comes from the company's main activities?

3. Financial Health of Gland Pharma Limited (5 min.)




What can you expect buying and holding a share of Gland Pharma Limited? (5 min.)

Welcome investor! Gland Pharma Limited's management wants to use your money to grow the business. In return you get a share of Gland Pharma Limited.

What can you expect buying and holding a share of Gland Pharma Limited?

First you should know what it really means to hold a share of Gland Pharma Limited. And how you can make/lose money.

Speculation

The Price per Share of Gland Pharma Limited is INR1,728. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Gland Pharma Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Gland Pharma Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR483.19. Based on the TTM, the Book Value Change Per Share is INR48.64 per quarter. Based on the YOY, the Book Value Change Per Share is INR76.16 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Gland Pharma Limited.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.570.0%0.570.0%0.880.1%0.610.0%0.550.0%
Usd Book Value Change Per Share0.580.0%0.580.0%0.910.1%0.810.0%0.970.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.580.0%0.580.0%0.910.1%0.810.0%0.970.1%
Usd Price Per Share15.22-15.22-39.27-16.85-14.04-
Price to Earnings Ratio26.75-26.75-44.49-22.44-18.70-
Price-to-Total Gains Ratio26.08-26.08-42.97-29.04-29.04-
Price to Book Ratio2.62-2.62-7.53-3.41-2.85-
Price-to-Total Gains Ratio26.08-26.08-42.97-29.04-29.04-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share20.7402
Number of shares48
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.580.81
Usd Total Gains Per Share0.580.81
Gains per Quarter (48 shares)28.0138.81
Gains per Year (48 shares)112.06155.22
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101121020155145
202242140310300
303363260466455
404484380621610
505605500776765
606726620931920
70784774010871075
80896886012421230
901009998013971385
10011211110015521540

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%6.00.00.0100.0%6.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%6.00.00.0100.0%6.00.00.0100.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.06.00.0%0.00.06.00.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%6.00.00.0100.0%6.00.00.0100.0%

Fundamentals of Gland Pharma Limited

About Gland Pharma Limited

Gland Pharma Limited engages in manufacturing and sale of injectable formulation in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical API products including synthesis of complex drug molecules, such as LMWH, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro intestinal, gynecological, hormones, neuro/Cns, ophthal/ontological, and other areas, as well as pain and analgesics, respirator, and vitamins, minerals and nutrients; and offers contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Fundamental data was last updated by Penke on 2024-04-09 11:12:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Gland Pharma Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Gland Pharma Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Gland Pharma Limited to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 21.5% means that ₹0.22 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Gland Pharma Limited:

  • The MRQ is 21.5%. The company is making a huge profit. +2
  • The TTM is 21.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ21.5%TTM21.5%0.0%
TTM21.5%YOY27.6%-6.1%
TTM21.5%5Y26.2%-4.7%
5Y26.2%10Y25.2%+1.0%
1.1.2. Return on Assets

Shows how efficient Gland Pharma Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Gland Pharma Limited to the Drug Manufacturers - General industry mean.
  • 8.9% Return on Assets means that Gland Pharma Limited generated ₹0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Gland Pharma Limited:

  • The MRQ is 8.9%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 8.9%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ8.9%TTM8.9%0.0%
TTM8.9%YOY15.5%-6.6%
TTM8.9%5Y14.3%-5.4%
5Y14.3%10Y13.7%+0.6%
1.1.3. Return on Equity

Shows how efficient Gland Pharma Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Gland Pharma Limited to the Drug Manufacturers - General industry mean.
  • 9.8% Return on Equity means Gland Pharma Limited generated ₹0.10 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Gland Pharma Limited:

  • The MRQ is 9.8%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 9.8%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ9.8%TTM9.8%0.0%
TTM9.8%YOY16.9%-7.1%
TTM9.8%5Y16.1%-6.3%
5Y16.1%10Y15.7%+0.5%

1.2. Operating Efficiency of Gland Pharma Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Gland Pharma Limited is operating .

  • Measures how much profit Gland Pharma Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Gland Pharma Limited to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 30.9% means the company generated ₹0.31  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Gland Pharma Limited:

  • The MRQ is 30.9%. The company is operating very efficient. +2
  • The TTM is 30.9%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ30.9%TTM30.9%0.0%
TTM30.9%YOY36.9%-6.0%
TTM30.9%5Y36.0%-5.2%
5Y36.0%10Y35.3%+0.7%
1.2.2. Operating Ratio

Measures how efficient Gland Pharma Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 0.76 means that the operating costs are ₹0.76 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Gland Pharma Limited:

  • The MRQ is 0.758. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.758. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.758TTM0.7580.000
TTM0.758YOY0.681+0.077
TTM0.7585Y0.689+0.069
5Y0.68910Y0.692-0.004

1.3. Liquidity of Gland Pharma Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Gland Pharma Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 9.46 means the company has ₹9.46 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Gland Pharma Limited:

  • The MRQ is 9.464. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.464. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.464TTM9.4640.000
TTM9.464YOY10.055-0.590
TTM9.4645Y8.374+1.091
5Y8.37410Y7.739+0.634
1.3.2. Quick Ratio

Measures if Gland Pharma Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Gland Pharma Limited to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 9.10 means the company can pay off ₹9.10 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Gland Pharma Limited:

  • The MRQ is 9.100. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 9.100. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ9.100TTM9.1000.000
TTM9.100YOY12.750-3.651
TTM9.1005Y9.044+0.056
5Y9.04410Y8.179+0.866

1.4. Solvency of Gland Pharma Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Gland Pharma Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Gland Pharma Limited to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.09 means that Gland Pharma Limited assets are financed with 9.3% credit (debt) and the remaining percentage (100% - 9.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Gland Pharma Limited:

  • The MRQ is 0.093. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.093. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.093TTM0.0930.000
TTM0.093YOY0.086+0.007
TTM0.0935Y0.113-0.020
5Y0.11310Y0.124-0.011
1.4.2. Debt to Equity Ratio

Measures if Gland Pharma Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Gland Pharma Limited to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 10.3% means that company has ₹0.10 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Gland Pharma Limited:

  • The MRQ is 0.103. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.103. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.103TTM0.1030.000
TTM0.103YOY0.094+0.008
TTM0.1035Y0.130-0.027
5Y0.13010Y0.144-0.014

2. Market Valuation of Gland Pharma Limited

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Gland Pharma Limited generates.

  • Above 15 is considered overpriced but always compare Gland Pharma Limited to the Drug Manufacturers - General industry mean.
  • A PE ratio of 26.75 means the investor is paying ₹26.75 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Gland Pharma Limited:

  • The EOD is 36.448. Based on the earnings, the company is overpriced. -1
  • The MRQ is 26.746. Based on the earnings, the company is overpriced. -1
  • The TTM is 26.746. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD36.448MRQ26.746+9.703
MRQ26.746TTM26.7460.000
TTM26.746YOY44.488-17.742
TTM26.7465Y22.436+4.310
5Y22.43610Y18.696+3.739
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Gland Pharma Limited:

  • The EOD is 202.116. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 148.311. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 148.311. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD202.116MRQ148.311+53.805
MRQ148.311TTM148.3110.000
TTM148.311YOY200.648-52.337
TTM148.3115Y91.496+56.815
5Y91.49610Y76.247+15.249
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Gland Pharma Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 2.62 means the investor is paying ₹2.62 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Gland Pharma Limited:

  • The EOD is 3.577. Based on the equity, the company is fair priced.
  • The MRQ is 2.625. Based on the equity, the company is underpriced. +1
  • The TTM is 2.625. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.577MRQ2.625+0.952
MRQ2.625TTM2.6250.000
TTM2.625YOY7.531-4.906
TTM2.6255Y3.414-0.789
5Y3.41410Y2.845+0.569
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Gland Pharma Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--48.63748.6370%76.156-36%67.371-28%80.532-40%
Book Value Per Share--483.193483.1930%434.556+11%334.256+45%302.936+60%
Current Ratio--9.4649.4640%10.055-6%8.374+13%7.739+22%
Debt To Asset Ratio--0.0930.0930%0.086+8%0.113-18%0.124-25%
Debt To Equity Ratio--0.1030.1030%0.094+9%0.130-21%0.144-29%
Dividend Per Share----0%-0%-0%-0%
Eps--47.41947.4190%73.563-36%51.173-7%45.893+3%
Free Cash Flow Per Share--8.5518.5510%16.310-48%16.288-48%14.757-42%
Free Cash Flow To Equity Per Share--9.4579.4570%18.429-49%31.810-70%27.653-66%
Gross Profit Margin--0.9650.9650%0.9660%0.9680%0.9690%
Intrinsic Value_10Y_max--151.963--------
Intrinsic Value_10Y_min---156.324--------
Intrinsic Value_1Y_max--16.096--------
Intrinsic Value_1Y_min--8.023--------
Intrinsic Value_3Y_max--47.700--------
Intrinsic Value_3Y_min--3.732--------
Intrinsic Value_5Y_max--78.507--------
Intrinsic Value_5Y_min---22.855--------
Market Cap284678270676.800+27%208894735896.000208894735896.0000%539041480331.200-61%231227901470.720-10%192689917892.267+8%
Net Profit Margin--0.2150.2150%0.276-22%0.262-18%0.252-15%
Operating Margin--0.3090.3090%0.369-16%0.360-14%0.353-13%
Operating Ratio--0.7580.7580%0.681+11%0.689+10%0.692+9%
Pb Ratio3.577+27%2.6252.6250%7.531-65%3.414-23%2.845-8%
Pe Ratio36.448+27%26.74626.7460%44.488-40%22.436+19%18.696+43%
Price Per Share1728.350+27%1268.2501268.2500%3272.650-61%1403.840-10%1169.867+8%
Price To Free Cash Flow Ratio202.116+27%148.311148.3110%200.648-26%91.496+62%76.247+95%
Price To Total Gains Ratio35.536+27%26.07626.0760%42.973-39%29.045-10%29.045-10%
Quick Ratio--9.1009.1000%12.750-29%9.044+1%8.179+11%
Return On Assets--0.0890.0890%0.155-42%0.143-38%0.137-35%
Return On Equity--0.0980.0980%0.169-42%0.161-39%0.157-37%
Total Gains Per Share--48.63748.6370%76.156-36%67.371-28%80.532-40%
Usd Book Value--955046640.000955046640.0000%858914520.000+11%660667656.000+45%598763560.000+60%
Usd Book Value Change Per Share--0.5840.5840%0.914-36%0.808-28%0.966-40%
Usd Book Value Per Share--5.7985.7980%5.215+11%4.011+45%3.635+60%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.5690.5690%0.883-36%0.614-7%0.551+3%
Usd Free Cash Flow--16901880.00016901880.0000%32238000.000-48%32194464.000-48%29167440.000-42%
Usd Free Cash Flow Per Share--0.1030.1030%0.196-48%0.195-48%0.177-42%
Usd Free Cash Flow To Equity Per Share--0.1130.1130%0.221-49%0.382-70%0.332-66%
Usd Market Cap3416139248.122+27%2506736830.7522506736830.7520%6468497763.974-61%2774734817.649-10%2312279014.707+8%
Usd Price Per Share20.740+27%15.21915.2190%39.272-61%16.846-10%14.038+8%
Usd Profit--93725160.00093725160.0000%145399680.000-36%101145216.000-7%90708700.000+3%
Usd Revenue--434952120.000434952120.0000%526097400.000-17%383935440.000+13%351547500.000+24%
Usd Total Gains Per Share--0.5840.5840%0.914-36%0.808-28%0.966-40%
 EOD+4 -4MRQTTM+0 -0YOY+7 -275Y+10 -2410Y+15 -19

3.2. Fundamental Score

Let's check the fundamental score of Gland Pharma Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1536.448
Price to Book Ratio (EOD)Between0-13.577
Net Profit Margin (MRQ)Greater than00.215
Operating Margin (MRQ)Greater than00.309
Quick Ratio (MRQ)Greater than19.100
Current Ratio (MRQ)Greater than19.464
Debt to Asset Ratio (MRQ)Less than10.093
Debt to Equity Ratio (MRQ)Less than10.103
Return on Equity (MRQ)Greater than0.150.098
Return on Assets (MRQ)Greater than0.050.089
Total7/10 (70.0%)

3.3. Technical Score

Let's check the technical score of Gland Pharma Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.667
Ma 20Greater thanMa 501,779.998
Ma 50Greater thanMa 1001,804.040
Ma 100Greater thanMa 2001,858.053
OpenGreater thanClose1,756.700
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets87,775,350
Total Liabilities8,188,130
Total Stockholder Equity79,587,220
 As reported
Total Liabilities 8,188,130
Total Stockholder Equity+ 79,587,220
Total Assets = 87,775,350

Assets

Total Assets87,775,350
Total Current Assets69,008,080
Long-term Assets18,767,270
Total Current Assets
Cash And Cash Equivalents 19,088,950
Short-term Investments 19,273,010
Net Receivables 8,715,330
Inventory 19,453,000
Other Current Assets 2,477,790
Total Current Assets  (as reported)69,008,080
Total Current Assets  (calculated)69,008,080
+/-0
Long-term Assets
Property Plant Equipment 17,361,030
Intangible Assets 116,610
Long-term Assets Other 1,064,410
Long-term Assets  (as reported)18,767,270
Long-term Assets  (calculated)18,542,050
+/- 225,220

Liabilities & Shareholders' Equity

Total Current Liabilities7,291,330
Long-term Liabilities896,800
Total Stockholder Equity79,587,220
Total Current Liabilities
Short-term Debt 7,090
Short Long Term Debt 5,600
Accounts payable 5,873,500
Other Current Liabilities 924,660
Total Current Liabilities  (as reported)7,291,330
Total Current Liabilities  (calculated)6,810,850
+/- 480,480
Long-term Liabilities
Long term Debt 32,610
Capital Lease Obligations 6,320
Long-term Liabilities  (as reported)896,800
Long-term Liabilities  (calculated)38,930
+/- 857,870
Total Stockholder Equity
Common Stock164,700
Retained Earnings 60,153,880
Other Stockholders Equity 19,268,640
Total Stockholder Equity (as reported)79,587,220
Total Stockholder Equity (calculated)79,587,220
+/-0
Other
Capital Stock164,700
Cash and Short Term Investments 38,361,960
Common Stock Shares Outstanding 164,680
Current Deferred Revenue486,080
Liabilities and Stockholders Equity 87,775,350
Net Debt -19,044,420
Net Invested Capital 79,625,430
Net Working Capital 61,716,750
Property Plant and Equipment Gross 17,361,030
Short Long Term Debt Total 44,530



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-31
> Total Assets 
0
29,294,680
35,235,490
40,860,390
64,960,820
78,336,210
87,775,350
87,775,35078,336,21064,960,82040,860,39035,235,49029,294,6800
   > Total Current Assets 
14,081,500
17,321,630
23,574,560
28,462,900
51,236,420
58,520,790
69,008,080
69,008,08058,520,79051,236,42028,462,90023,574,56017,321,63014,081,500
       Cash And Cash Equivalents 
0
3,728,410
2,364,020
1,694,970
4,918,200
3,158,240
19,088,950
19,088,9503,158,2404,918,2001,694,9702,364,0203,728,4100
       Short-term Investments 
0
2,782,990
4,843,450
11,427,280
19,546,850
29,268,930
19,273,010
19,273,01029,268,93019,546,85011,427,2804,843,4502,782,9900
       Net Receivables 
4,609,980
5,307,930
5,520,480
7,767,320
12,726,780
12,514,660
8,715,330
8,715,33012,514,66012,726,7807,767,3205,520,4805,307,9304,609,980
       Inventory 
3,787,190
5,128,300
9,118,760
7,562,790
12,751,680
11,856,670
19,453,000
19,453,00011,856,67012,751,6807,562,7909,118,7605,128,3003,787,190
       Other Current Assets 
298,000
5,681,930
7,248,330
10,540
1,292,910
1,722,290
2,477,790
2,477,7901,722,2901,292,91010,5407,248,3305,681,930298,000
   > Long-term Assets 
0
11,973,050
11,660,930
12,397,490
13,724,400
19,815,420
18,767,270
18,767,27019,815,42013,724,40012,397,49011,660,93011,973,0500
       Property Plant Equipment 
10,327,310
10,426,500
10,950,260
11,969,020
13,244,420
17,268,970
17,361,030
17,361,03017,268,97013,244,42011,969,02010,950,26010,426,50010,327,310
       Intangible Assets 
0
0
0
0
125,350
125,350
116,610
116,610125,350125,3500000
       Long-term Assets Other 
0
1,546,550
710,670
411,860
19,957,310
836,150
1,064,410
1,064,410836,15019,957,310411,860710,6701,546,5500
> Total Liabilities 
0
5,191,090
6,615,500
4,398,040
5,928,400
6,760,000
8,188,130
8,188,1306,760,0005,928,4004,398,0406,615,5005,191,0900
   > Total Current Liabilities 
2,533,840
3,791,890
5,327,690
3,590,230
5,125,280
5,820,250
7,291,330
7,291,3305,820,2505,125,2803,590,2305,327,6903,791,8902,533,840
       Short-term Debt 
0
5,080
6,200
10,170
2,970
2,610
7,090
7,0902,6102,97010,1706,2005,0800
       Short Long Term Debt 
0
4,260
5,300
8,910
1,350
1,120
5,600
5,6001,1201,3508,9105,3004,2600
       Accounts payable 
1,892,890
2,918,110
4,461,980
2,490,940
4,007,250
4,628,500
5,873,500
5,873,5004,628,5004,007,2502,490,9404,461,9802,918,1101,892,890
       Other Current Liabilities 
532,450
739,700
749,470
171,170
63,250
552,570
924,660
924,660552,57063,250171,170749,470739,700532,450
   > Long-term Liabilities 
0
1,399,200
1,287,810
807,810
803,120
939,750
896,800
896,800939,750803,120807,8101,287,8101,399,2000
       Capital Lease Obligations Min Short Term Debt
0
7,150
5,210
340
6,290
5,490
-770
-7705,4906,2903405,2107,1500
> Total Stockholder Equity
0
24,103,590
28,619,990
36,462,350
59,032,420
71,576,210
79,587,220
79,587,22071,576,21059,032,42036,462,35028,619,99024,103,5900
   Common Stock
154,950
154,950
154,950
154,950
163,590
164,300
164,700
164,700164,300163,590154,950154,950154,950154,950
   Retained Earnings Total Equity0000000
   Accumulated Other Comprehensive Income 
0
0
0
160,280
240,930
114,540
-15,590
-15,590114,540240,930160,280000
   Capital Surplus 0000000
   Treasury Stock0000000
   Other Stockholders Equity 
14,180
5,939,740
5,937,580
5,889,940
18,401,090
18,953,920
19,268,640
19,268,64018,953,92018,401,0905,889,9405,937,5805,939,74014,180



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue36,246,010
Cost of Revenue-16,854,270
Gross Profit19,391,74019,391,740
 
Operating Income (+$)
Gross Profit19,391,740
Operating Expense-10,611,470
Operating Income8,844,4008,780,270
 
Operating Expense (+$)
Research Development403,770
Selling General Administrative485,320
Selling And Marketing Expenses270,320
Operating Expense10,611,4701,159,410
 
Net Interest Income (+$)
Interest Income1,794,170
Interest Expense-74,470
Other Finance Cost-1,794,170
Net Interest Income-74,470
 
Pretax Income (+$)
Operating Income8,844,400
Net Interest Income-74,470
Other Non-Operating Income Expenses0
Income Before Tax (EBT)10,545,8207,142,980
EBIT - interestExpense = 11,110,430
10,545,820
7,884,900
Interest Expense74,470
Earnings Before Interest and Taxes (EBIT)11,184,90010,620,290
Earnings Before Interest and Taxes (EBITDA)12,652,260
 
After tax Income (+$)
Income Before Tax10,545,820
Tax Provision-2,735,390
Net Income From Continuing Ops7,810,4307,810,430
Net Income7,810,430
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses27,465,740
Total Other Income/Expenses Net1,701,42074,470
 

Technical Analysis of Gland Pharma Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Gland Pharma Limited. The general trend of Gland Pharma Limited is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Gland Pharma Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Gland Pharma Limited.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 1,846 < 1,865 < 1,879.

The bearish price targets are: 1,712 > 1,677 > 1,671.

Tweet this
Gland Pharma Limited Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Gland Pharma Limited. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Gland Pharma Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Gland Pharma Limited. The current macd is -15.33669131.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Gland Pharma Limited price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Gland Pharma Limited. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Gland Pharma Limited price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Gland Pharma Limited Daily Moving Average Convergence/Divergence (MACD) ChartGland Pharma Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Gland Pharma Limited. The current adx is 17.13.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Gland Pharma Limited shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Gland Pharma Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Gland Pharma Limited. The current sar is 1,809.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Gland Pharma Limited Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Gland Pharma Limited. The current rsi is 41.67. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Gland Pharma Limited Daily Relative Strength Index (RSI) ChartGland Pharma Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Gland Pharma Limited. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Gland Pharma Limited price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Gland Pharma Limited Daily Stochastic Oscillator ChartGland Pharma Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Gland Pharma Limited. The current cci is -119.8702517.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Gland Pharma Limited Daily Commodity Channel Index (CCI) ChartGland Pharma Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Gland Pharma Limited. The current cmo is -24.60495655.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Gland Pharma Limited Daily Chande Momentum Oscillator (CMO) ChartGland Pharma Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Gland Pharma Limited. The current willr is -90.10167464.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Gland Pharma Limited Daily Williams %R ChartGland Pharma Limited Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Gland Pharma Limited.

Gland Pharma Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Gland Pharma Limited. The current atr is 52.94.

Gland Pharma Limited Daily Average True Range (ATR) ChartGland Pharma Limited Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Gland Pharma Limited. The current obv is 8,792,434.

Gland Pharma Limited Daily On-Balance Volume (OBV) ChartGland Pharma Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Gland Pharma Limited. The current mfi is 12.03.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Gland Pharma Limited Daily Money Flow Index (MFI) ChartGland Pharma Limited Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Gland Pharma Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-06ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-26BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-28BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

6.3. Candlestick Patterns

Gland Pharma Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Gland Pharma Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.667
Ma 20Greater thanMa 501,779.998
Ma 50Greater thanMa 1001,804.040
Ma 100Greater thanMa 2001,858.053
OpenGreater thanClose1,756.700
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Gland Pharma Limited with someone you think should read this too:
  • Are you bullish or bearish on Gland Pharma Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Gland Pharma Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Gland Pharma Limited

I send you an email if I find something interesting about Gland Pharma Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Gland Pharma Limited.

Receive notifications about Gland Pharma Limited in your mailbox!